Oral Cladribine versus Placebo in RRMS
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Cladribine
DNA inhibitor
What it measured
Main measures
The primary endpoint is qualifying relapse rate at 96 weeks
Relapses
Who could take part
Relapsing MS
Inclusion: The subjects must fulfill all of the following criteria prior to Study Day 1: Exclusion: The subjects must not meet any of the following criteria:
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate the efficacy of Cladribine versus Placebo in the reduction of qualifying relapse rate during 96 weeks of treatment in subjects with RRMS.
Papers
Loading reviews and guidelines…
Related trials
- HiHat
Phase 2 · Recruiting
Still running
- MS700568_0198
Phase 4 · Not yet recruiting
Still running
- Cladribine Tablets Level of Response Predictors in Clinic…
Running, not recruiting
Still running
- ADAs to Alemtuzumab
Completed
No result found
- A Study to Learn More About The Safety of Diroximel Fumar…
Running, not recruiting
Still running
- COAST
Phase 2 · Stopped early
Stopped early
History
Started
Apr 2005
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error